This article is more than 5 years old. Information may no longer be current.
Study suggests OCT-guided reinjection of bevacizumab for macular edema
Der Ophthalmologe. 2008;105(12):1121-1126.
Click Here to Manage Email Alerts
Half of patients treated with intravitreal bevacizumab had complete resolution of macular edema due to retinal vein occlusion, and re-treatment based on optical coherence tomography findings appeared to produce stable or improved vision, according to a study.
Of 63 patients receiving a 2.5-mg intravitreal injection of Avastin (bevacizumab, Genentech), 31 had complete resolution of macular edema after the first injection with an improvement of 3.7 ± 3.7 lines in visual acuity. Of these patients, 65.2% developed a recurrence of macular edema within 13.3 ± 4.4 weeks.
Per protocol, patients were reinjected with bevacizumab if OCT showed persistent or recurrent macular edema. All patients reinjected with bevacizumab for a recurrence had resolution of macular edema, with visual gains after first reinjection similar to the initial injection. There was a second recurrence of macular edema after 13.4 ± 5.4 weeks in 69% of patients.
All 32 patients who failed initial therapy were re-treated with bevacizumab. One-third of patients had resolution of macular edema after reinjection, but all relapsed after 13.9 ± 4.1 weeks.